Related Experiment Video
Updated: Apr 29, 2026
05:00
Author Spotlight: Enhancing Multicolor Fluorescence Localization in Lung Carcinoma Sample
Published on: November 21, 2023
3.0K
High-grade lung adenocarcinomas with micropapillary and/or solid patterns: a review.
Vicente Morales-Oyarvide1, Mari Mino-Kenudson
1aClinic of Thoracic Oncology, Instituto Nacional de Cancerologia, México City, Mexico bDepartment of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Current Opinion in Pulmonary Medicine
|May 24, 2014
Summary
Lung adenocarcinoma with solid and micropapillary patterns indicate poor survival. Early detection and targeted therapies are crucial for improving outcomes in these aggressive lung cancers.
Area of Science:
- Oncology
- Pulmonary Medicine
- Cancer Research
Background:
- Lung adenocarcinoma is a major cause of cancer mortality.
- Histopathological patterns, including solid and micropapillary features, influence prognosis.
- Understanding these patterns is key to improving patient outcomes.
Purpose of the Study:
- To review recent findings on lung adenocarcinomas featuring solid and micropapillary patterns.
- To highlight the clinical and molecular implications of these histological subtypes.
Main Methods:
- Review of recent scientific literature and studies.
- Analysis of clinicopathological features, radiologic characteristics, and molecular alterations.
- Correlation of histological patterns with patient survival and treatment response.
Main Results:
- Solid and micropapillary patterns are linked to adverse features like invasion and metastasis, predicting poor survival.
- Radiologic findings, including high F-fluorodeoxyglucose uptake, can aid in detecting these patterns.
- Micropapillary patterns are associated with EGFR mutations, while solid patterns correlate with KRAS mutations, impacting targeted therapy efficacy.
Conclusions:
- Solid and micropapillary patterns in lung adenocarcinoma signify a high risk of recurrence and reduced survival.
- Preoperative identification of these patterns, development of KRAS-targeted therapies, and biomarker discovery are essential.
- Effective treatment strategies are needed for patients with these aggressive lung adenocarcinoma subtypes.
